Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is N/A as of 2026-10-06T19:37:15.660Z.
Calculation as of: 2026-10-06T19:37:15.660Z.
Quote observation: 2026-10-06T19:26:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f3e61b787222715dff3a983a87307d60b14e7521dca9159fec0ee57fbd3bd529
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-24.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
N/A
EV/ASSETS RATIO AVG TTM
N/A
EV/ASSETS RATIO AVG 3Y
N/A
EV/ASSETS RATIO AVG 5Y
N/A
EV/ASSETS RATIO AVG 10Y
N/A
EV/ASSETS RATIO AVG 15Y
N/A
EV/ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lakewood-Amedex Biotherapeutics, Inc.
Market Cap
$1.51M
EV/Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45M
EV/Assets Ratio
N/A
TTM Avg
0.31x
3Y Avg
12009020.49x
5Y Avg
12009020.49x
Market Cap
$1.42M
EV/Assets Ratio
0.06x
TTM Avg
0.17x
3Y Avg
0.33x
5Y Avg
1.09x
Market Cap
$1.36M
EV/Assets Ratio
0.43x
TTM Avg
6.21x
3Y Avg
231.74x
5Y Avg
231.74x
Market Cap
$1.31M
EV/Assets Ratio
N/A
TTM Avg
8.54x
3Y Avg
5.32x
5Y Avg
3.94x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lakewood-Amedex Biotherapeutics, Inc. (LABT) | $1.51M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.46M | N/A | 0.36x | 0.41x | 0.71x |
| PMGC Holdings Inc. (ELAB)vs › | $1.45M | N/A | 0.31x | 12009020.49x | 12009020.49x |
| NEXGEL, Inc. (NXGL)vs › | $1.45M | 0.32x | 0.99x | 1.48x | 1.31x |
| INVO Fertility, Inc. (IVF)vs › | $1.42M | 0.06x | 0.17x | 0.33x | 1.09x |
| Silo Pharma, Inc. (SILO)vs › | $1.60M | N/A | 0.14x | 0.30x | 0.55x |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.36M | 0.43x | 6.21x | 231.74x | 231.74x |
| NewcelX Ltd. (NCEL)vs › | $1.33M | 0.10x | 2.04x | 93.17x | 147.80x |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.31M | N/A | 8.54x | 5.32x | 3.94x |
| Genprex, Inc. (GNPX)vs › | $1.33M | N/A | 0.61x | 0.57x | 1.01x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-09-24 | 0.02x |
| 2026-09-23 | 0.01x |
| 2026-09-22 | 0.07x |
| 2026-09-21 | 0.09x |
| 2026-09-18 | 0.07x |
| 2026-09-17 | 0.03x |
| 2026-09-16 | 0.10x |
| 2026-09-15 | 0.12x |
| 2026-09-14 | 0.11x |
| 2026-09-11 | 0.13x |
| 2026-09-10 | 0.09x |
| 2026-09-09 | 0.16x |
| 2026-09-08 | 0.12x |
| 2026-09-04 | 0.04x |
| 2026-09-03 | 0.04x |
| 2026-09-02 | 0.09x |
| 2026-09-01 | 0.29x |
| 2026-08-31 | 0.21x |
| 2026-08-28 | 0.16x |
| 2026-08-27 | 0.21x |
| 2026-08-26 | 0.20x |
| 2026-08-25 | 0.15x |
| 2026-08-24 | 0.11x |
| 2026-08-21 | 0.14x |
| 2026-08-20 | 0.13x |
| 2026-08-19 | 0.14x |
| 2026-08-18 | 0.16x |
| 2026-08-17 | 0.12x |
| 2026-08-14 | 0.15x |
